文献速递心脑血管急症

心房颤动患者接受经皮冠状动脉介入治疗后的出血预防

Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
PubMed 文献 · N Engl J Med · 2016-11-14
一句话结论房颤患者PCI支架置入后,利伐沙班15mg每日一次联合P2Y12抑制剂或利伐沙班2.5mg每日两次联合双联抗血小板治疗,较维生素K拮抗剂联合双联抗血小板治疗显著降低临床显著出血,三组心血管死亡、心肌梗死或卒中发生率相似。

PIONEER AF-PCI随机将2124例接受PCI支架置入的非瓣膜性房颤患者按1:1:1分为三组:利伐沙班15mg每日一次联合P2Y12抑制剂12个月、利伐沙班2.5mg每日两次联合双联抗血小板治疗1、6或12个月、剂量调整维生素K拮抗剂联合双联抗血小板治疗1、6或12个月。主要安全性终点临床显著出血发生率分别为16.8%、18.0%和26.7%,两种利伐沙班方案均低于标准治疗(HR 0.59,95%CI 0.47-0.76;HR 0.63,95%CI 0.50-0.80)。心血管死亡、心肌梗死或卒中发生率三组相似。观察到的宽置信区间降低了疗效结论的确定性。

要点

  • 房颤患者PCI支架置入后,利伐沙班15mg每日一次联合P2Y12抑制剂12个月组临床显著出血16.8%,低于维生素K拮抗剂联合双联抗血小板治疗组的26.7%(HR 0.59,95%CI 0.47-0.76,P<0.001)。
  • 利伐沙班2.5mg每日两次联合双联抗血小板治疗1、6或12个月组临床显著出血18.0%,低于标准治疗组的26.7%(HR 0.63,95%CI 0.50-0.80,P<0.001)。
  • 心血管死亡、心肌梗死或卒中发生率三组相似:利伐沙班15mg组6.5%、利伐沙班2.5mg组5.6%、维生素K拮抗剂组6.0%,所有比较P值均无统计学意义。
  • 作者指出,观察到的宽置信区间降低了关于疗效的任何结论的确定性。

适用人群与场景

  • 接受经皮冠状动脉介入治疗并置入支架的非瓣膜性心房颤动患者。

诊断标准与关键阈值

  • 主要安全性终点为临床显著出血,定义为TIMI标准的大出血或小出血,或需要医疗关注的出血。

处置流程与药物剂量

  • 组1:利伐沙班15mg每日一次联合P2Y12抑制剂,治疗12个月。
  • 组2:利伐沙班2.5mg每日两次联合双联抗血小板治疗,治疗1、6或12个月。
  • 组3:剂量调整维生素K拮抗剂每日一次联合双联抗血小板治疗,治疗1、6或12个月。

研究设计与关键结果

  • PIONEER AF-PCI为随机对照试验,纳入2124例接受PCI支架置入的非瓣膜性房颤患者,按1:1:1随机分为三组。
  • 主要安全性终点临床显著出血:组1为16.8%,组2为18.0%,组3为26.7%;组1 vs 组3 HR 0.59(95%CI 0.47-0.76,P<0.001);组2 vs 组3 HR 0.63(95%CI 0.50-0.80,P<0.001)。
  • 心血管死亡、心肌梗死或卒中发生率:组1为6.5%,组2为5.6%,组3为6.0%,所有比较P值均无统计学意义。

证据类型、等级与局限

  • 证据类型:随机对照试验。
  • 作者指出,观察到的宽置信区间降低了关于疗效的任何结论的确定性。

对床旁实践的改变

  • 对于接受PCI支架置入的非瓣膜性房颤患者,利伐沙班15mg每日一次联合P2Y12抑制剂12个月或利伐沙班2.5mg每日两次联合双联抗血小板治疗1、6或12个月,与维生素K拮抗剂联合双联抗血小板治疗1、6或12个月相比,临床显著出血发生率更低,而心血管死亡、心肌梗死或卒中发生率相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) with placement of stents, standard anticoagulation with a vitamin K antagonist plus dual antiplatelet therapy (DAPT) with a P2Y12 inhibitor and aspirin reduces the risk of thrombosis and stroke but increases the risk of bleeding. The effectiveness and safety of anticoagulation with rivaroxaban plus either one or two antiplatelet agents are uncertain.

METHODS: We randomly assigned 2124 participants with nonvalvular atrial fibrillation who had undergone PCI with stenting to receive, in a 1:1:1 ratio, low-dose rivaroxaban (15 mg once daily) plus a P2Y12 inhibitor for 12 months (group 1), very-low-dose rivaroxaban (2.5 mg twice daily) plus DAPT for 1, 6, or 12 months (group 2), or standard therapy with a dose-adjusted vitamin K antagonist (once daily) plus DAPT for 1, 6, or 12 months (group 3). The primary safety outcome was clinically significant bleeding (a composite of major bleeding or minor bleeding according to Thrombolysis in Myocardial Infarction [TIMI] criteria or bleeding requiring medical attention).

RESULTS: The rates of clinically significant bleeding were lower in the two groups receiving rivaroxaban than in the group receiving standard therapy (16.8% in group 1, 18.0% in group 2, and 26.7% in group 3; hazard ratio for group 1 vs. group 3, 0.59; 95% confidence interval [CI], 0.47 to 0.76; P<0.001; hazard ratio for group 2 vs. group 3, 0.63; 95% CI, 0.50 to 0.80; P<0.001). The rates of death from cardiovascular causes, myocardial infarction, or stroke were similar in the three groups (Kaplan-Meier estimates, 6.5% in group 1, 5.6% in group 2, and 6.0% in group 3; P values for all comparisons were nonsignificant).

CONCLUSIONS: In participants with atrial fibrillation undergoing PCI with placement of stents, the administration of either low-dose rivaroxaban plus a P2Y12 inhibitor for 12 months or very-low-dose rivaroxaban plus DAPT for 1, 6, or 12 months was associated with a lower rate of clinically significant bleeding than was standard therapy with a vitamin K antagonist plus DAPT for 1, 6, or 12 months. The three groups had similar efficacy rates, although the observed broad confidence intervals diminish the surety of any conclusions regarding efficacy. (Funded by Janssen Scientific Affairs and Bayer Pharmaceuticals; PIONEER AF-PCI ClinicalTrials.gov number, NCT01830543 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

参考来源

  1. Gibson CM, Mehran R, Bode C, et al. Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI. N Engl J Med. 2016. PMID: 27959713. doi:10.1056/NEJMoa1611594

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。